Pando Software Begins Pre-Registration of Three New P2E Pandonia Universes
28.4.2022 07:24:00 EEST | Business Wire | Press release
The new P2E Pandonia Universe starts pre-registration ahead of its simultaneous worldwide release. The three Pandonia Universes include ‘Pandonia Arena,’ ‘Guardians of Pandonia,’ and ‘Dragons of Pandonia.’ Pre-registration is available now on https://pandonia.co.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220426006357/en/
Three new P2E Pandonia Universes have started pre-registration ahead of their worldwide release. The three Pandonia Universes include ‘Pandonia Arena,’ ‘Guardians of Pandonia,’ and ‘Dragons of Pandonia.’ Pre-registration is available now on the official website. (Graphic: Business Wire)
‘Pandonia Arena’ with unique heroes
‘Pandonia Arena’ was issued as non-fungible tokens (NFT) for heroes with distinctive visuals and unique skills. The control method that allows anyone to play easily, such as battle royale mode, big boss mode, and crown mode, is a huge advantage. The global No.1 Arcade NFT-based P2E game ‘Pandonia Arena’ will be released in May.
New collectible RPG, P2E game ‘Guardians of Pandonia’
‘Guardians of Pandonia’ is a mobile collectible RPG where you can create your own team with up to six characters and enjoy adventures, raids, and PvP content. In particular, there are high expectations for this new collectible P2E game in Japan, so it is planned to be released in June.
MMORPG 'Dragons of Pandonia,' a story created with a variety of dragons
‘Dragons of Pandonia’ is an MMORPG focused on dragons. It is the P2E-based MMORPG where users write their own huge and powerful stories relying on five different occupation types and various dragons. Development is underway aiming at a global launch in July.
Special benefits for pre-registrants of the three Pandonia Universes
For pre-registered users, Pando Software has announced that it will provide game-related privileges along with an airdrop event in which 10,000 mPANDO will be drawn and distributed, fitting the game's official release date.
In the three new Pandonia Universes, users can acquire mPANDO through gameplay as well as through other games currently being serviced by Pando Software. mPANDO is a MainNet coin and is designed to be used for various in-game applications.
Starting with the ‘Legend of Pandonia’ as its first P2E project in 2022, Pando Software has continued with the ‘I Love Pandonia’ release to the global market.
The detailed schedule and news about the three Pandonia Universes can be checked on the official website (https://pandonia.co).
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220426006357/en/
Contact information
Pando Software Inc
Lucia Tanti
+82-70-5100-0815
pr@pandosoft.co.kr
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 17:00:00 EEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 16:34:00 EEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 12:00:00 EEST | Press release
Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely with healthcare authorities and other stakeholders to support timely access for people with Parkinson’s disease who continue to experience moderate to severe motor fluctuations despite current oral therapies. Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. Despite availab
MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 11:16:00 EEST | Press release
The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav
New Daiichi Sankyo Data Underscore the Effect of Bempedoic Acid in the Real-World Management of Dyslipidemia and Cardiovascular risk28.8.2026 11:00:00 EEST | Press release
Daiichi Sankyo (TSE:4568) today announced new results from the MILOS study that demonstrate the real-world impact of bempedoic acid administered either alone or as a fixed-dose combination with ezetimibe, in the management of dyslipidaemia. Presented at the European Society of Cardiology Congress 2026 in Munich, the findings show that the clinically relevant reductions in low-density lipoprotein cholesterol (LDL-C) achieved within the first year of treatment are estimated to translate into clinically meaningful reductions in 10-year cardiovascular (CV) risk.1 The data further reinforce the clinical value of bempedoic acid, and its fixed-dose combination with ezetimibe, across a diverse range of patient subtypes, regardless of gender and glycaemic profile (diabetes, pre-diabetes, or normoglycemia).2,3 Key findings from the new analyses of the MILOS study include: 10-year CV risk estimate reduction: An analysis of 960 at-risk patients estimated that one year of bempedoic acid-add-on ther
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom